Abciximab biosimilar - ISU Abxis
Alternative Names: ClotinabLatest Information Update: 24 Oct 2020
Price :
$50 *
At a glance
- Originator ISU Abxis
- Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ischaemic heart disorders
- Discontinued Myocardial infarction
Most Recent Events
- 24 Oct 2020 Discontinued - Phase-II for Myocardial infarction (In the elderly, In adults) in South Korea (IV)
- 01 May 2013 Phase-II clinical trials in Myocardial infarction (In adults, In the elderly) in South Korea (IV) (NCT03087539)